A Phase 2 Efficacy Study of an Oral, Potent and Selective T-Type Calcium (Cav3) Modulator in Essential Tremor Patients (T-CALM): Design and Dose Selection Rationale

被引：0
|
作者：
Papapetropoulos, Spiridon [1 ]
Maricich, Yuri [1 ]
Lee, Margaret [1 ]
Boyer, Stacey [1 ]
Silver, Bruce [1 ]
机构：
[1] Cavion Inc, Cambridge, MA USA
来源：
NEUROLOGY | 2018年 / 90卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P6.060
引用
收藏
页数：2
相关论文
共 9 条
  • [1] A Phase 2 Efficacy Study of CX-8998, a Potent and Selective T-Type Calcium (Cav3) Modulator in Parkinson's disease Tremor (PDT) Patients: Design and Dose-Selection Rationale
    Papapetropoulos, S.
    Lee, M.
    Boyer, S.
    Versavel, M.
    [J]. MOVEMENT DISORDERS, 2018, 33 : S14 - S14
  • [2] Efficacy Result from a Phase 2, Double-Blind, Placebo-Controlled Study of CX-8998 a State-Dependent T-Type Calcium (Cav3) Channel Modulator in Essential Tremor Patients (T-CALM)
    Papapetropoulos, Spyros
    Lee, Margaret
    Boyer, Stacey
    Krouse, Andrew
    Pahwa, Rajesh
    Lyons, Kelly
    Ondo, William
    Jinnah, H.
    Elble, Rodger
    [J]. NEUROLOGY, 2019, 92 (15)
  • [3] A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of CX-8998, a Selective Modulator of the T-Type Calcium Channel in Inadequately Treated Moderate to Severe Essential Tremor: T-CALM Study Design and Methodology for Efficacy Endpoint and Digital Biomarker Selection
    Papapetropoulos, Spyros
    Lee, Margaret S.
    Boyer, Stacey
    Newbold, Evan J.
    [J]. FRONTIERS IN NEUROLOGY, 2019, 10
  • [4] A Phase 2a Study of CX-8998, an Oral, Potent and Selective T-Type Calcium Modulator in Adolescents and Young Adults with Absence Epilepsy: Rationale for population and dose selection
    Papapetropoulos, Spiridon
    Lee, Margaret
    Boyer, Stacey
    Versavel, Mark
    [J]. NEUROLOGY, 2018, 90
  • [5] Efficacy and Safety of the T-Type Calcium Channel Modulator CX-8998 in T-CALM, a Randomized, Double-Blind, Placebo-Controlled, Phase 2a Trial in Participants with Essential Tremor
    Ondo, William
    Papapetropoulos, Spyros
    Lee, Margaret S.
    Versavel, Stacey
    Krouse, Andrew
    Newbold, Evan
    Jinnah, Hyder A.
    Pahwa, Rajesh
    Lyons, Kelly E.
    Zesiewicz, Theresa
    Hedera, Peter
    Handforth, Adrian
    Elder, Jenna
    Versavel, Mark
    Elble, Rodger
    [J]. ANNALS OF NEUROLOGY, 2020, 88 : S175 - S175
  • [6] Proof-of-Concept, Double-Blind, Placebo-Controlled Study for CX-8998, a State-Dependent T-Type Calcium (TTCC) Modulator in Essential Tremor Patients (T-CALM): Efficacy and Safety Results
    Papapetropoulos, Spyros
    Boyer, Stacey
    Lee, Margaret S.
    [J]. NEUROTHERAPEUTICS, 2019, 16 (03) : 917 - 917
  • [7] A Proof-of-Principle Quantitative EEG Study of an Oral, Potent and Selective T-Type Calcium Modulator in Healthy Volunteers
    Papapetropoulos, Spiridon
    Boyer, Stacey
    Lee, Margaret
    [J]. NEUROLOGY, 2018, 90
  • [8] Proof-of-Principle Quantitative EEG Study of CX-8998, an Oral, Potent and Selective T-Type Calcium antagonist in development for symptomatic treatment of Essential Tremor and Parkinson's disease Tremor
    Papapetropoulos, S.
    Lee, M.
    Boyer, S.
    [J]. MOVEMENT DISORDERS, 2018, 33 : S22 - S22
  • [9] EFFICACY AND SAFETY OF ACT-280778, A DUAL L- AND T-TYPE CALCIUM CHANNEL BLOCKER, IN PATIENTS WITH MILD-TO-MODERATE ESSENTIAL HYPERTENSION: RESULTS FROM A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE-CONTROLLED TRIAL (REDUCE-1)
    Dingemanse, J.
    Otasevic, P.
    Shakeri-Nejad, K.
    Klainman, E.
    Putnikovic, B.
    Kracker, H.
    Mueller, M.
    Zimlichman, R.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S33 - S33
1